This price cut will benefit many prostate cancer patients to adhere to the treatment, it added.
“Our goal is to make a preferred choice of therapy such as Obynx accessible and more accessible to people suffering from cancer. Bridging these unfulfilled gaps comes from our patient-first approach,” Sharyd Patel, MD, told Zydus Cadila.
Enzalutamide is a preferred option among patients with significant liver, heart and kidney diseases, which is very common in older men. It has an advantage to be taken through oral route, Zydus Cadila said.
The drug has been developed in-house and offers bioavailability benefits in a soft gel capsule, different from the hard gelatin capsules found in the country, it added.
Prostate cancer is one of the leading cancers in men in India and the risk increases with age, the company says.
Shares of Cadila Healthcare, the listed unit of the Zydus Group, traded at Rs 320.35 per share. Scrip on BSE, down 0.39 percent over prior closure.